Improved Survival of Advanced‐Stage Anaplastic Thyroid Cancer With Systemic Therapy
The Laryngoscope · 2024
DOI: 10.1002/lary.31712 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Lauran K Evans und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Objectives
Anaplastic thyroid cancer (ATC) is the most aggressive and fatal thyroid malignancy. Currently, there still exists a paucity of literature studying the relationship between available ATC‐targeted therapy, immunotherapy, and survival. We aim to investigate how systemic therapies affect survival outcomes in ATC.
Methods
A single‐tertiary‐institution chart review of patients diagnosed with advanced‐stage ATC, and who underwent surgery as part of their treatment, was performed between 2000 and 2023, with 41 patients included. Demographics, clinical characteristics, and survival data were collected and analyzed via Kaplan–Meier and Cox proportional hazards analyses.
Results
54% of patients were female, and average age was 67.4 years old. The most common mutations identified were BRAF (15 patients), p53 (9 patients), and p63 (2 patients). A total of 18 patients utilized targeted or immunotherapy, with Trametinib and Dabrafenib (9 patients) as the most common agents used. Two‐year overall survival was 24%, and 5‐year overall survival was 23%, with median survival time of 7.6 months. Kaplan–Meier analysis demonstrated improved survival in patients who received chemotherapy ( p = 0.048). Cox proportional hazards analysis demonstrated that patients treated with immunotherapy or targeted therapy had a statistically significant increase in survival compared with patients who did not receive these therapies ( p = 0.016). Additionally, females and those with a p63 mutation demonstrated improved survival outcomes ( p = 0.010, p = 0.001).
Conclusions
Targeted therapy and immunotherapy use should be strongly considered when treating patients with ATC. Further studies into novel drugs targeting immune checkpoints and combination therapy are needed to better optimize treatment of patients with ATC. Level of Evidence 3 Laryngoscope , 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Department of Biostatistics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Department of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
ORCID-Profile: Lauran K Evans, Maie St John
Förderung
- NCI NIH HHS
- NIDCD NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Evans, L. K., Chen, H., Taki Labib, M., Cronkite, D. A., Yu, A. C., Ashendouek, M., Elashoff, D., Chai-Ho, W., Wong, D. J., & St John, M. (2024). Improved Survival of Advanced‐Stage Anaplastic Thyroid Cancer With Systemic Therapy. The Laryngoscope. https://doi.org/10.1002/lary.31712
Vancouver
Evans LK, Chen H, Taki Labib M, Cronkite DA, Yu AC, Ashendouek M, et al. Improved Survival of Advanced‐Stage Anaplastic Thyroid Cancer With Systemic Therapy. The Laryngoscope. 2024. doi:10.1002/lary.31712
BibTeX
@article{Evans2024,
author = {Evans, Lauran K and Chen, Haidee and Taki Labib, Manwel and Cronkite, D Alexander and Yu, Alice C and Ashendouek, Maya and Elashoff, David and Chai-Ho, Wanxing and Wong, Deborah J and St John, Maie},
title = {Improved Survival of Advanced‐Stage Anaplastic Thyroid Cancer With Systemic Therapy},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31712}
}
EUVIMED